EMA recommends approval of 10 new medicines

The Committee for Medicinal Products for Human Use (CHMP) of the EMA (European Medicines Agency) recommended the approval of 10 medicines at its meeting in June 2024. These include Balversa (erdafitinib) for urothelial carcinoma and Eurneffy (epinephrine), the first nasal spray for allergic emergencies. Read more here

If you need more information on regulatory issues, ELS can certainly help.

Please do not hesitate to contact your local ELS consultant or via email info@elssolutions.pt

Contact us

We will contact you as soon as possible.